Cardinal Health and Industry Competition

The pharmaceutical and generic drug industries are highly competitive and, simultaneously, tremendously risk oriented. Both of these characteristics are significantly present in the current outlook for Cardinal Health. The producer of generic drugs is a Fortune 500 company which, according to Leger (2012), pulls in roughly $103 billion in revenue on an annual basis. However, the company is also the target of fierce competition from fellow pharmaceutical giants such as the McKesson Corporation and Amerisource Bergen and is the target of troubling legal charges that threaten to impact both its reputation and its profitability. As the discussion here will demonstrate, the above-noted competitors have seized a relative competitive advantage over Cardinal Health. The discussion assesses the nature of the challenges thereby imposed upon Cardinal Health.

First and foremost among the challenges facing Cardinal Health is its own internal and legal crisis. At present, the company...
[ View Full Essay]